Induction Therapy: A Modern Review of Kidney Transplantation Agents

Cheguevara Afaneh*, Meredith J Aull1, Sebastian Schubl1,2, David B Leeser1 and Sandip Kapur1

Abstract

Kidney transplantation remains the most effective modality for the treatment of end-stage renal disease. The development of induction therapy has significantly reduced the incidence of acute rejection within the first six months following kidney transplantation. As a result, induction therapy is typically administered in the majority of kidney transplants. Moreover, early graft function has also improved with the advent and routine administration of induction therapy. Effective induction therapy has also expanded the donor pool as it allows for more effective utilization of marginal donor kidneys including expanded criteria donors and donors after cardiac death. It may also benefit higher immunologic risk recipients such as highly sensitized, African American, and repeat transplant patients. Poly- and monoclonal antibody agents are available for use as induction agents, including rabbit Anti-thymocyte globulin, interleukin-2 receptor antagonists, and alemtuzumab each of which have proven efficacy but have discrete advantages and disadvantages. Tailoring induction therapy to individual patient profiles provides the best opportunity for both short and long-term outcomes of the patient and allograft. Moreover, we explore the role of induction therapy with long-term steroid avoidance immunosuppression regimens in modern kidney transplantation. Overall, we review the safety and efficacy of this important group of induction agents and discuss an approach to tailoring their use for specific patients undergoing kidney transplantation.

Introduction

Historically, acute rejection episodes were most prevalent in the early postoperative period. Prior to induction therapy, kidney transplantation was plagued with high rates of acute rejection. Early attempts at preventing acute rejection consisted only of glucocorticoids and azathoprine. However, advancements in the understanding of kidney transplantation immunology lead to the development of “induction therapy.” Induction therapy refers to any potent immunosuppressive agent administered in the perioperative period to prevent episodes of acute rejection and immunologically-mediated causes of graft loss. The widespread use of these agents has significantly decreased the incidence of acute rejection in the first six months; however, long-term allograft survival has not yet been prolonged by the agents used in modern kidney transplantation [1].

In 1995 induction therapy was used in less than half of all kidney transplants in the United States, a decade later, approximately 70% of all kidney transplant recipients received induction therapy [2]. Induction therapy carries various risks, the most serious of which is overimmunosuppression resulting in infection or malignancy [3,4]. Appropriate selection and dosing of induction therapy can prevent acute rejection episodes, postpone the onset of acute rejection outside the critical perioperative period, potentially decrease the degree of ischemia-reperfusion injury, and graft function [5,6]. The latter has become increasingly important as major transplant centers continue to utilize marginal donor kidneys, including expanded criteria donors (ECD) and donation after cardiac death (DCD) donors. Additionally, induction therapy has benefited patients at higher risk of acute rejection, including those that are highly sensitized, African American, or undergoing retransplantation [7,8]. Nevertheless, despite the decrease in acute rejection episodes and improvement in early graft function, overall allograft survival has not been clearly shown to improve with induction therapy.

Induction therapy commonly refers to antibodies against specific or non-specific antigens on targeted immune cells (Table 1). These can be classified as lymphocyte depleting agents and non-lymphocyte depleting agents. The categorization is based on the ability of the therapeutic agent to target specific antigens or cells, leading to a decrease in the total cellular expression or reduction in cell counts. Most depleting agents are relatively potent with potential for toxicity with prolonged administration (i.e. OKT3). On the other hand, non-depleting agents are generally well-tolerated with reasonable side effect profiles, yet are less potent (i.e. anti-interleukin-2 receptor antibody). Depleting agents are also used for severe or refractory cases of acute rejection and have proven to be more effective than glucocorticoids in treating these episodes of acute rejection [9]. Polyclonal antibodies are typically heterogeneous, with batch-to-batch variability, variable in-vivo reactions, typically require larger doses, and are less susceptible to immune elimination (Figure 1). Monoclonal antibodies are more consistent, predictable, and require smaller doses. Murine monoclonal antibodies are susceptible to immune elimination, but chimeric (e.g. basiliximab) and especially humanized (e.g. alemtuzumab, daclizumab) antibodies are less susceptible to immune elimination. Some major institutions have modified their immunosuppression regimen to avoid long-term steroid maintenance. These regimens have utilized more potent induction agents (i.e. rabbit Antithymocyte globulin [rATG]) even in higher risk patients, such as the elderly or patients with multiple co-morbidities. The armamentarium of induction agents in modern transplantation has expanded, leading to the clinical dilemma in selecting the most appropriate agent for a given patient while taking into account co-morbidities, donor quality, immunological status, and planned maintenance therapy.

The importance of induction therapy compared to transplantation without induction therapy has been clearly demonstrated and routinely accepted. The following review focuses on the three most commonly used induction agents in modern kidney transplantation, including rATG, basiliximab, and alemtuzumab. The advantages...
and disadvantages of each agent will be discussed in the following review in the context of tailoring induction therapy to specific patient populations.

**Rabbit-Antithymocyte Globulin (rATG)**

Although several polyclonal depleting antibodies are commercially available, rATG remains the most commonly utilized therapeutic induction agent, although not specifically approved for this indication. This heterologous polyclonal antibody formulation is created by immunizing rabbits with human thymocytes, which act as immunogens [10]. Rabbit serum is gathered and purified, leaving only the IgG isotypes. Given the non-specificity of this process, multiple intended and non-intended antigens are targeted. rATG can bind CD2, CD3, CD4, CD5, CD8, CD11a, CD18, CD28, CD45, and CD40L on T cells, as well as CD16, CD20, CD56, and the major histocompatibility molecules (class I and II) [10,11]. T cell depletion is critical to the efficacy of rATG; however, the exact assortment of mechanisms of this agent is not fully understood. The bound T cells are cleared via the reticuloendothelial system of the spleen and liver [12]. The effects of lymphocyte depletion can persist for months to years, as the serum half-life of rATG is at least several weeks [13-15]. rATG has been used as both induction therapy (off-label) and FDA-approved treatment modality for acute rejection.

Rabbit ATG is most effective when the first dose is administered prior to vascular anastomosis at the time of allograft transplantation. Ensuring timely dosing can minimize ischemia-reperfusion injury and mitigate the development of delayed graft function (DGF) [16]. The typical dosing regimen for rATG is 1.5 mg/kg/dose for 3 to 5 days with an optimal dose of 6 mg/kg [17-20]. Nevertheless, various protocols have included a variety of dosing regimens from 1 to 6 mg/kg/dose given anywhere from 1 to 10 days [13,17-20]. These include infectious complications, such as cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), and varicella, as well as lymphomas, such as post-transplant lymphoproliferative disorder (PTLD) [21,22].

The first infusion of rATG can elicit flu-like symptoms in addition to an allergic reaction. The mildest form of this reaction simply includes fever and chills; however, this may lead to a syndrome called cytokine release syndrome (Figure 2), which is common to many lymphocyte depleting polyclonal antibodies. Cytokine release syndrome can also include various vague symptoms, such as nausea, urticaria, rash, and headache; however, more severe cases can include the development of dyspnea, hypotension, pulmonary edema, or even anaphylaxis [10,23]. In a prospective randomized study examining single bolus antithymocyte globulin (9mg/kg/dose) compared to basiliximab, patients treated with the single bolus antithymocyte globulin had a lower rate of delayed graft function (5.7% versus 15.9% in the basiliximab-treated group, P<0.025); however, experienced significant hemodynamic and pulmonary disturbances without significantly reducing the incidence of acute rejection, improving patient or graft survival [24]. Given the potential for such side effects, patients with significant pulmonary or cardiac disease may not be suitable candidates to receive rATG, as their physiologic reserve is limited. Premedicating the patient with corticosteroids, acetaminophen, and antihistamine prior to initial infusions as well as slow administration of rATG via a central venous catheter can significantly reduce the occurrence and/ or intensity of cytokine release syndrome. Following administration of rATG patients should be monitored daily for leucopenia, neutropenia, and thrombocytopenia which are typically dose-related and generally resolve within days following dose reduction [25]. Global over-immunosuppression has been linked to both CMV infection, which is most prevalent in the first year posttransplant, and malignancies, such as PTLD [26]. Infectious prophylaxis is necessary given the significant immunosuppression associated with rATG, thus patients are usually maintained on antiviral, antibacterial, and antifungal prophylaxis in the perioperative period and when the agent is being administered for an episode of acute rejection.
Basiliximab

Basiliximab is one of the most commonly utilized non-depleting monoclonal antibody induction agents. Basiliximab is a chimeric mouse-human monoclonal IgG1 antibody to the α-subunit of the IL-2 receptor, or CD25. Inhibition of IL-2 binding to the intended receptor occurs through steric hindrance, which does not lead to lymphocyte depletion, but rather prevention of early T cell activation [27]. Since basiliximab is partially humanized and targets activated T cells exhibiting CD25 on the cell-surface, it is generally well tolerated with a favorable side effect profile. Because of its specificity for naïve T cells, basiliximab should be limited to induction therapy use only, as it is not efficacious for treatment of acute rejection.

In contrast to rATG, basiliximab is administered only twice in the perioperative period (20 mg per dose). The first dose is administered

<table>
<thead>
<tr>
<th>Author</th>
<th>No. of Patients</th>
<th>Induction Therapy</th>
<th>Maintenance Therapy</th>
<th>Acute Rejection at 1 year</th>
<th>Patient Survival</th>
<th>Graft Survival</th>
<th>Infections</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brennan et al. [7]</td>
<td>141 137</td>
<td>rATG Basiliximab</td>
<td>Csa MMF Prednisone</td>
<td>rATG: 15.6% Basiliximab: 25.5% P=0.02</td>
<td>At 1 year: rATG: 95.7% Basiliximab: 95.6% No significant difference</td>
<td>At 1 year: rATG: 90.8% Basiliximab: 89.6% No significant difference</td>
<td>rATG: 85.8% Basiliximab: 75.2% P=0.03</td>
<td>No difference in incidence of cancer between the groups</td>
</tr>
<tr>
<td>Cantarovich et al. [57]</td>
<td>99 CSWD 98 CCS</td>
<td>rATG rATG</td>
<td>Csa MMF +/- prednisone</td>
<td>At 1 year: CSWD: 17.3% CCS: 7.1% P=0.031</td>
<td>At 1 year: CSWD: 97.1% CCS: 99.0% No significant difference</td>
<td>At 1 year: CSWD: 94.9% CCS: 93.2% No significant difference</td>
<td>At 1 year: CSWD: 67.3% CCS: 72.8% No significant difference</td>
<td>The CCS group had a trend towards a higher incidence of malignancy at 1 year (P=0.029).</td>
</tr>
<tr>
<td>Cianco et al. [59]</td>
<td>100 100</td>
<td>rATG/DAC rATG/C1H</td>
<td>FK EC-MPS</td>
<td>rATG/DAC: 11% rATG/C1H: 9% No significant difference</td>
<td>At 4 years: rATG/DAC: 96% rATG/C1H: 92% No significant difference</td>
<td>At 4 years: rATG/DAC: 91% rATG/C1H: 83% No significant difference</td>
<td>At 1 year: rATG/DAC: 22% rATG/C1H: 21% No significant difference</td>
<td>No cases of PTLD occurred in either group</td>
</tr>
<tr>
<td>Hanaway et al. [51]</td>
<td>251: 70 high risk 164 low risk</td>
<td>C1H (high and low risk patients) rATG (high risk patients only) Basiliximab (low risk patients only)</td>
<td>FK C1H Early steroid withdrawal</td>
<td>Low risk patients: C1H vs. basiliximab (3% vs. 20%, P&lt;0.001) High risk patients: C1H vs. rATG (11% vs. 13%, P=0.53)</td>
<td>At 3 years: C1H 96% Basiliximab 98% rATG 91% No significant difference</td>
<td>At 3 years: C1H 95% Basiliximab 94% rATG 91% No significant difference</td>
<td>At 3 years: C1H 35% Basiliximab 41% rATG 22% High risk (P=0.009): C1H 60% rATG 80%</td>
<td>Incidence of cancer was significantly higher in the C1H group compared to rATG or basiliximab (P=0.03)</td>
</tr>
<tr>
<td>Lebranchu et al. [33]</td>
<td>50 50</td>
<td>rATG Basiliximab</td>
<td>Csa MMF Prednisone (withdrawn at 6 months)</td>
<td>rATG: 8% Basiliximab: 10% No significant difference</td>
<td>At 1 year: rATG: 100% Basiliximab: 98% No significant difference</td>
<td>At 1 year: rATG: 96% Basiliximab: 94% No significant difference</td>
<td>At 1 year: rATG: 86.0% Basiliximab: 64.7% No significant difference</td>
<td>No cases of cancer occurred in either group</td>
</tr>
<tr>
<td>Mourad et al. [35]</td>
<td>53 52</td>
<td>rATG Basiliximab</td>
<td>Csa MMF Prednisone</td>
<td>rATG: 9.4% Basiliximab: 9.6% No significant difference</td>
<td>At 1 year: rATG: 98.1% Basiliximab: 98.1% No significant difference</td>
<td>At 1 year: rATG: 96.2% Basiliximab: 94.2% No significant difference</td>
<td>At 1 year: rATG: 53.0% Basiliximab: 42.3% No significant difference</td>
<td>No cases of PTLD occurred in either group</td>
</tr>
<tr>
<td>Woodle et al. [37]</td>
<td>CSWD group (n=191) CCS group (n=195)</td>
<td>rATG 125 CSWD 136 CCS IL-2RA 66 CSWD 59 CCS</td>
<td>FK MMF +/- prednisone</td>
<td>CSWD: rATG: 14.4% Basiliximab: 24.2% P=0.09 At 5 years: CSWD: 94.2% CCS: 93.3% P=0.058</td>
<td>At 5 years: CSWD: 94.2% CCS: 96.4% No significant difference</td>
<td>CSWD: 39.3% CCS: 44.1% No significant difference</td>
<td>No difference in incidence of cancer between the CSWD and CCS groups</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Summary of Induction Therapy Trials and Agent Comparisons.
Cytokine Release Syndrome. Antibody activation and cytokine release. Antibodies can bind antigens resulting in activation of the cell and cytokine release as illustrated in the figure.

Figure 2: Cytokine Release Syndrome. Antibody activation and cytokine release. Antibodies can bind antigens resulting in activation of the cell and cytokine release as illustrated in the figure.
hypotension and anaphylaxis have also been reported. Early studies utilizing alemtuzumab for multiple sclerosis was associated with the development of autoimmune thyroiditis [48] and similar findings have been noted in a renal transplant patient undergoing alemtuzumab induction therapy [49].

Alemutuzumab is only FDA-approved for the treatment of lymphoproliferative malignancies, although a common off-label use is induction therapy. Initial studies utilizing alemtuzumab for the treatment of acute rejection demonstrated significant infectious morbidity and mortality in patients maintained on triple maintenance immunosuppression therapy [50]. A recent prospective study (Table 2) compared the short-term results of alemtuzumab induction therapy to rATG and basiliximab in patients maintained on a steroid-sparing immunosuppression regimen [51]. Short-term data demonstrated lower rates of acute rejection at 6 months for patients at low-risk of developing acute rejection receiving alemtuzumab therapy compared with those receiving basiliximab. There was no difference in acute rejection rates between high immunologic risk patients receiving alemtuzumab versus those receiving rATG at 3 years. Patients receiving alemtuzumab did not experience an increased rate of adverse events. However, patients were excluded if they received kidneys from expanded-criteria donors, donation after cardiac death kidneys, and standard-criteria donors from kidneys with prolonged cold-ischemia times. Furthermore, the majority of transplants came from living donors, which traditionally have low rates of acute rejection. In the post hoc analysis alemtuzumab-treated patients had a trend toward higher rates of acute rejection compared to conventional induction agents between 1 and 3 years and the overall acute rejection rate reduction of alemtuzumab, compared to conventional induction therapy, was greatest in patients at low-risk of acute rejection.

Induction Therapy and the Steroid-Free Era

Minimizing global immunosuppression in the modern era of transplantation has become an important goal. The use of induction therapy has allowed for steroid-free long-term immunosuppression regimens and is gaining popularity world-wide. The goal of steroid-free immunosuppression is to decrease the negative cardiovascular profile associated with long-term administration of steroids. Specifically, steroid-free regimens should decrease the negative effects on blood pressure regulation as well serum glucose and lipid metabolism [52]. Moreover, the leading cause of death in kidney transplant patients is cardiovascular events [53].

The possible minimization of maintenance immunosuppression has been studied using basiliximab and rATG without compromising allograft outcomes. In the Astellas Steroid Withdrawal Study, patients assigned to the steroid-withdrawal arm and treated with rATG experienced a lower cumulative incidence of biopsy-proven acute rejection at 5 years compared to patients treated with basiliximab (Table 2) [37]. In this study, however, the investigators selected which antibody induction agent was used, thus raising the possibility that bias may have been introduced. In a smaller study using a steroid-avoidance immunosuppression regimen in HLA-matched donor/recipient pairs, basiliximab use has not lead to an increase in acute rejection episodes or the development of delayed graft function [38]. Moreover, only 1 patient (4%) developed post-transplant diabetes mellitus. In a study by Jaber et al. [54], kidney transplant recipients treated with rATG induction therapy and steroid-free immunosuppression demonstrated a cardiovascular risk factor reduction in four categories including the incidence of hypertension, hyperlipidemia, weight gain, and post-transplant diabetes mellitus, without compromising allograft survival or increasing the rate of acute rejection. Li and colleagues demonstrated the safety and efficacy of rATG and a steroid-free immunosuppression regimen in the pediatric population receiving a kidney transplant [55]. In this study, rATG was compared to an IL-2 receptor antibody utilizing a steroid-free regimen showing that rATG-treated patients did not develop acute rejection for the duration of the study or have an increased risk of clinical viral infection. Our transplant center’s experience utilizing induction therapy to enable steroid withdrawal has been very successful in a diverse population, using rATG in the majority of patients [56] and basiliximab in well-matched living donor recipients [38]. Cantarovich and colleagues demonstrated that patients administered rATG and maintained on a steroid-maintenance regimen had significantly lower rates of acute rejection compared to patients on a steroid-free immunosuppression regimen, although the incidence of malignancy, de novo diabetes, and hyperlipidemia were higher in steroid-maintenance group [57]. Patient and graft survival rates, as well as infectious complications in the first year were not significantly different between the two cohorts.

Alemutuzumab has also been studied in a steroid-sparing immunosuppression regimen and compared to both basiliximab and rATG. In the study by Hanaway et al. [51] (Table 2) as previously described, acute rejection rates were relatively low in low-risk patients receiving alemtuzumab compared to basiliximab, although the reduced immunologic risk profile of alemtuzumab was not evident in high risk patients treated with rATG. The overall rate of adverse events with alemtuzumab treated patients was similar to that of basiliximab or rATG treated patients over the 3 year study period (53% versus 50%, respectively; P=0.46). Moreover, the rate of cardiovascular events of all alemtuzumab treated patients compared to basiliximab or rATG was also similar (7% versus 10%, respectively; P=0.26), although the similarity was less evident in the high-risk immunologic group treated with rATG compared to alemtuzumab (12% versus 3%, respectively; P=0.06). Cai et al. [58] analyzed the United Network for Organ Sharing registry and found that recipients of alemtuzumab in conjunction with steroid-maintenance therapy had the lowest risk of graft failure, while patients administered an interleukin-2 receptor antagonist on a steroid-free immunosuppression regimen had the highest risk of graft failure. In a single-center, open-label randomized trial of 200 kidney transplant recipients (Table 2), Ciancio and colleagues compared dual induction therapy with rATG and daclizumab to dual therapy with rATG and alemtuzumab in patients maintained on steroid-free maintenance immunosuppression [59]. Lower doses of all induction therapy agents were used in both sets of patients. Patient and graft survival rates as well as acute rejection and infectious complication rates were not significantly different between the two groups. Moreover, none of these patients developed post-transplant lymphoproliferative disorder.

Summary

Induction therapy has become the standard of care at most major kidney transplant centers in the United States and abroad. The most frequently used agents include rATG, a polyclonal lymphocyte-depleting agent, and basiliximab, a monoclonal interleukin-2 receptor antagonist; however, there is renewed interest in alemtuzumab, a monoclonal antibody to CD52. Although induction therapy has not improved long-term patient and allograft survival, it has decreased the incidence of acute rejection and delayed graft function, which have both been shown to increase morbidity and affect short-term allograft outcomes. Additionally, administration of induction therapy has improved early graft function. Furthermore, potent induction therapy has been effective in avoiding long-term steroid use in immunosuppression regimens without increasing acute rejection rates.
or compromising long-term allograft function. Importantly, tailoring immunosuppression to each individual patient’s needs remains the most effective method of improving allograft function and maximizing patient outcomes.

References


